

December 17, 2018

Company Name: HEALIOS K.K.  
Representative: Hardy TS Kagimoto,  
Chairman & CEO  
(TSE Mothers Code: 4593)  
Contact: Ken Ishikawa  
Executive Officer in charge of administration  
(TEL: 03-5777-8308)

## **Announcement of Extension of Exclusive Negotiation Period with Athersys**

As announced in the press release on March 13, 2018, "[Healios and Athersys Announce Binding Letter of Intent to Expand MultiStem® Collaboration](#)", HEALIOS K.K. ("Healios") entered discussions to expand the exclusive license and option rights regarding MultiStem, the proprietary product of Athersys, Inc. ("Athersys").

On June 7, 2018, in the press release "[Announcement of Acquisition of MultiStem® License from Athersys](#)", Healios announced the acquisition of the license to develop and commercialize MultiStem as follows.

### Exclusive license

In Japan: Development and commercialization for Acute Respiratory Distress Syndrome ("ARDS")

Global: Development and commercialization of organ bud therapies using MultiStem

Global: Development and commercialization of MultiStem products for Ophthalmology indications

Global: Development and commercialization of combination iPS/ES derived cells with MultiStem products in Ophthalmology indications

In Japan: Development and commercialization of combination products of iPS derived organs with MultiStem (for limited organs)

In addition, Healios and Athersys have continued discussions about the option right to develop and commercialize MultiStem products in China.

Healios today announces that it agreed to make a \$2.0 million payment for an extension of the exclusive negotiation period through June 30, 2019. Healios can extend the exclusive negotiation period for another six months through December 31, 2019 by paying an additional \$3.0 million to Athersys. Such payments will be applied to the option fee for China, if applicable, and shall be creditable against milestone payments that Healios would pay for development progress for any licensed program, including ischemic stroke and ARDS in Japan.

### <Overview>

Healios will make the one-time payment of \$2.0 million within FY2018.

If matters to be disclosed arise in the future, Healios will promptly make any relevant announcements.